Animal Researche: 18pt;">Non-intoxicating cannabis compound CBD is a promising option for chronic pain.
CBD is one of the main therapeutic compounds present in cannabis plants. It may help alleviate different kinds of pain by:
- Interacting with pain receptors. CBD seems to interact with several nervous system receptors that control pain and inflammation.
- Boosting levels of anandamide – a pain-relieving endocannabinoid made by the human body.
- Boosting levels of adenosine – an anti-inflammatory, pain-reducing neurotransmitter.
Cannabidiol (CBD) is one of over 60 cannabinoids present in the Cannabis sativa (marijuana) plant. Cannabinoids are responsible for the health benefits of cannabis, with CBD being the second-most abundant cannabinoid after tetrahydrocannabinol (THC).
Unlike THC, CBD does not cause a high, making it ideal for reaping the benefits of marijuana without any of the mind-altering effects. Thanks to this, CBD has rapidly grown in popularity over the past several years. Some typical conditions CBD is used for include anxiety, depression, arthritis, insomnia, and treatment-resistant epilepsy.
In addition, CBD is widely used to relieve chronic pain, particularly when it is caused by difficult-to-treat conditions such as arthritis, multiple sclerosis, and herniated disks. This isn’t surprising since cannabis has been used as a pain reliever for thousands of years, and demonstrated to alleviate pain in clinical research.
How CBD Might Help With Pain
Interestingly enough, cannabidiol does not have any notable effects on the two known cannabinoid receptors of the endocannabinoid system (ECS) – CB1 and CB2. Instead, it seems to:
Interact with pain and inflammation receptors
Early research suggests that CBD interacts with several types of nervous system receptors that control pain and inflammation. Receptors are special proteins found in cells that respond to specific compounds, producing a biological effect. Most notably, studies show that CBD:
- Activates the TRPV1 (vanilloid) receptor which is particularly involved in inflammation-related pain. This desensitizes the receptor, leading to reduction of pain.1
- Blocks the GPR55 receptor which appears to be involved in the sensation of pain, and inflammatory joint pain in particular. 2
- Activates the α3 glycine receptor (GlyR), which suppresses inflammatory and neuropathic (nerve) pain. 3
Increase anandamide levels
CBD has been shown to increase the levels of anandamide – a neurotransmitter and the main cannabinoid compound produced inside the human body. One of anandamide’s main roles is to act as an analgesic (pain reliever). 4<
Increase adenosine levels
In addition, CBD also increases the levels of adenosine, a neurotransmitter that appears to be involved in pain, inflammation, and immune system function. This effect may explain how CBD inhibits the overactive immune response seen in rheumatoid arthritis. 5
In addition to this, MMA fighters and other athletes involved in strenuous training are beginning to use CBD to improve their workout recovery and reduce pain and soreness.
These uses are backed by animal and human research showing reduction of chronic pain and improvement of arthritis and MS-related pain in people taking CBD, other cannabinoids, or whole cannabis. 6 As one comprehensive review of dozens of studies summarizes, there is “conclusive or substantial evidence (ranging in modest to moderate effect) for benefit from cannabis or cannabinoids for chronic pain.” 7
Rodent studies report that CBD reduces pain and inflammation caused by arthritis and eye injury.
This study tested the use of transdermal (directly on the skin) CBD in a rat model of arthritis. CBD gel (0.6, 3.1, 6.2, or 62.3 mg) was applied daily for 4 days on the affected knee joints. CBD gel was found to reduce joint swelling, pain, and pro-inflammatory biomarker molecules in a dose-dependant manner, with the 6.2 and 62.3 mg doses having the strongest effect.
- The researchers concluded that “topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.” 9
This study examined whether CBD could help with eye pain. Mice with corneal injury had CBD or the CBD derivatives CBD-DMH and HU-308 applied directly to the eye. Both CBD and HU308 were found to reduce the blink response to capsaicin and movement of neutrophils into the eyes, indicating reduction of eye pain and inflammation.
- The researchers concluded that “CBD and HU308, could offer a novel therapy for ocular pain and inflammation with reduced CB1R mediated side-effects.” 10
This study examined the use of CBD for neuropathic pain caused by osteoarthritis (OA). Rats with OA were given CBD once or continually before the development of OA. CBD reduced joint inflammation and pain, and in the case of continuous use also prevented nerve damage and pain.
- The researchers concluded that “CBD may be a safe, useful therapeutic for treating OA joint neuropathic pain.” 11
This study examined the use of CBD in a rat model of rheumatoid arthritis. Rats were treated with CBD (5 – 40 mg/kg) for 3 days after the onset of arthritic inflammation. CBD was found to reduce edema (swelling) and hyperalgesia (pain sensitivity).
- The researchers concluded that “oral cannabidiol has a beneficial action on two symptoms of established inflammation: edema and hyperalgesia.” 12
This randomized, double-blind, placebo-controlled study examined the effectiveness of Sativex – a cannabis-based medicine containing THC and CBD – in rheumatoid arthritis (RA). A total of 58 people were given Sativex or placebo daily for 5 weeks. The treatment group saw significant improvement of pain, sleep quality, and overall RA activity.
- The researchers concluded that “In the first ever controlled trial of a CBM in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following Sativex treatment.” 13
In this study, 7 elderly patients (mean age of 65) with chronic pain related to a kidney transplant were given 100-300 mg daily CBD dosages for 3 weeks. Two of the patients experienced complete pain improvement, four had partial pain improvement for the first 15 days, and one patient had no change.
- The researchers concluded that “During this follow-up, CBD was well-tolerated, and there were no severe adverse effects.” 14
This randomized, double-blind, placebo-controlled study, tested the analgesic effects of a CBD gel in people with osteoarthritis (OA). A total of 320 people (average age 62) with knee OA were given placebo, 250 mg, or 500 mg of ZYN002, a synthetic CBD gel, daily for 12 weeks. The gel was not significantly better than placebo at improving the average worst pain score. However, further analysis showed that more people saw improvement with the gel (53% vs 34% for placebo), and men (but not women) treated with 250 mg experienced a significant improvement of pain.
- The researchers concluded that “…while ZYN002 250 mg/day produced numerically better mean reductions from baseline in average worst knee pain scores, it was not statistically different from placebo.” 15
Dosage for Painl>
Read more: Advantages and disadvantages of different CBD forms
Supplements in Review Recommendationl>
We highly recommend CBD for pain management. Although human studies of CBD are just beginning, existing research on cannabis and cannabinoids suggest that it is a promising option for relieving chronic pain, especially when we consider CBD’s lack of intoxication and dependence.
There is no established dosage of CBD for pain. Because there’s little research it is best to start with dosages recommended by CBD supplements. Most CBD products recommend starting with 15 – 25 mg, after which you can increase dosage until you feel the desired analgesic effects.
- Costa B et al. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol. 2004 Sep;143(2):247-50. ↩
- Schuelert N and McDougall JJ. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci Lett. 2011 Aug 1;500(1):72-6. ↩
- Xiong W et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med. 2012 Jun 4;209(6):1121-34. ↩
- Deutsch DG. A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs). Front Pharmacol. 2016 Oct 13;7:370. eCollection 2016. ↩
- Booz GW. Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress. Free Radic Biol Med. 2011 Sep 1; 51(5): 1054–1061. ↩
- Iskedjian M et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007 Jan;23(1):17-24. ↩
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda.Washington (DC): National Academies Press (US); 2017 Jan 12. ↩
- Kindred JH et al. Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation. Complement Ther Med. 2017 Aug;33:99-104. ↩
- Hammell DC et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016 Jul;20(6):936-48. ↩
- Dinesh Thapa et al. The Non-psychoactive Phytocannabinoid, Cannabidiol (CBD), and the Synthetic Derivatives, HU308 and CBD-DMH, Reduces Hyperalgesia and Inflammation in a Mouse Model of Corneal injury. FASEB Vol. 31, No. 1_supplementApril 2017. ↩
- Holly T. Philpott et al. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017 Dec; 158(12): 2442–2451. ↩
- Costa B et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):294-9. ↩
- Blake DR et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):50-2. ↩
- Cuñetti L et al. Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplant Proc. 2018 Mar;50(2):461-464. ↩
- D. Hunter et al. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. OARSI April 2018Volume 26, Supplement 1, Page S26. ↩